Patients with probable chronic kidney transplant rejection will be randomly assigned to four treatment groups: 1) placebo; 2) irbesartan; 3) pravastatin; 4) irbesartan and paravastatin. The hypothesis will test whether the combination of irbesartan and paravastatin are effective in slowing the progression of chronic kidney allograft rejection.
Showing the most recent 10 out of 380 publications